https://www.thebodypro.com/author/myles-helfand
Myles Helfand Img

Myles Helfand

Executive Editor

Myles is the executive editor and general manager of TheBody/TheBodyPro. A career journalist and editor, Myles joined TheBody in 2001 as a part-time copyeditor. He has since established himself as a leading journalist and content strategist on HIV-related issues, authoring hundreds of articles and editing hundreds more -- and accumulating an ever-growing mountain of HIV conference badges along the way.

Latest by Myles Helfand

Juan Berenguer, M.D., Ph.D. and Antonio Urbina, M.D.
Interviews

Immediate HIV Treatment Initiation With Integrase Inhibitors Leads to Large Drop in Secondary HIV Transmission Among MSM

Integrase inhibitors are known to be potent first-line therapy options. Recent research suggests their benefits extend to onward HIV prevention as well.

By Terri Wilder, M.S.W. and Myles Helfand
disparity
News

This Week in HIV Research: Disclosing Our Disparities

Sept. 17, 2020: HIV prevalence gaps between Latinx people and non-Latinx white people; Obamacare awareness and perceptions among HIV clinicians; the relationship between pain and HIV; cancer mortality trends among PLWH.

By Barbara Jungwirth and Myles Helfand
dapivirine vaginal ring
News

This Week in HIV Research: Where the Rubber Meets the Ring

Sep. 10, 2020: Concomitant use of vaginal rings with condoms; benefits of more frequent HIV screening for young MSM; Black MSM, substance use, and the PrEP continuum; HIV outcomes stratified by anti-LGTBQ policy across U.S. states.

By Barbara Jungwirth and Myles Helfand
Hep C virus
News

This Week in HIV Research: Hep C, That Other Epidemic Within an Epidemic

Sep. 3, 2020: A hepatitis C microelimination program for people living with HIV; PrEP concentrations and gender-affirming hormones; a collaborative intervention to improve opioid prescribing practices; TDF and fracture risk.

By Barbara Jungwirth and Myles Helfand
doctor with trans patient
News

This Week in HIV Research: When Treating Trans Patients, Check Your Priors

Aug. 27, 2020: Traditional CVD risk calculation tools falter for transgender women; switching to B/F/TAF despite NRTI resistance; how tenofovir has altered the HBV landscape; syndemic effects on viral load and blood pressure.

By Barbara Jungwirth and Myles Helfand
brain dissipation
News

This Week in HIV Research: What We Don’t Know Hurts Them

Aug. 20, 2020: HIV knowledge and stigma among health care workers in the southern U.S.; condomless sex vs. HIV risk among MSM; how drug class choice may affect onward transmission risk; STI screening rates among MSM on PrEP.

By Barbara Jungwirth and Myles Helfand
mouth to ear
News

This Week in HIV Research: Why Aren’t We Listening to Ourselves?

Aug. 13, 2020: HCV testing rates among people newly diagnosed with HIV; HCV treatment referrals ammong coinfected people; HIV mortality rates despite free treatment access; mysterious, plummeting CD4 test results.

By Barbara Jungwirth and Myles Helfand
pulling back curtain
News

This Week in HIV Research: Life in the Integrase Era

Aug. 6, 2020: Recent trends in drug interaction rates; integrase inhibitors and cardiac event risk; a deep dive into HIV drug resistance in Florida; frailty symptoms and neurocognitive disorders amidst high CD4 counts.

By Barbara Jungwirth and Myles Helfand
solving maze
Research

This Week in HIV Research: Solving the Riddle of Poor PrEP Uptake

July 30, 2020: HIV prevention shortfalls among adolescents of color; PrEP use among trans people; PrEP information gaps among women of color; the case for vacation-based (a.k.a. episodic) PrEP.

By Barbara Jungwirth and Myles Helfand
mental connection
Research

This Week in HIV Research: The Mind Matters

July 23, 2020: Depression and HIV risk mitigation among MSM; a consistent HIV provider is good for CD4 and viral load; spirituality and HIV prevention; HCV treatment access and reinfection risk.

By Barbara Jungwirth and Myles Helfand